NON-MUSCLE INVASIVE BLADDER CANCER

This study tests a new treatment called cretostimogene grenadenorepvec for people with a type of bladder cancer (non-muscle invasive) that did not get better after standard therapy (BCG). The treatment uses a modified virus to attack cancer cells. About 190 adults will take part …

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific gene change (FGFR3). The goal is to find a safe dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to standard tre…

This study tests a new treatment called cretostimogene grenadenorepvec, a virus that targets cancer cells, to see if it can keep intermediate-risk bladder cancer from returning after surgery. About 367 people will be randomly assigned to receive the virus or just be watched. The …

This study tests a combination of two drugs—BCG (a standard immunotherapy) and durvalumab (a newer immunotherapy)—in 100 adults with high-risk non-muscle-invasive bladder cancer who have not received BCG before. The goal is to see if the combination is safe and effective at contr…

This study tests whether adding the immunotherapy drug sasanlimab to standard BCG treatment can better control high-risk, early-stage bladder cancer and prevent it from coming back. About 1,068 participants with non-muscle invasive bladder cancer are involved, some receiving the …

This early-phase trial tests a new treatment called CG0070, a virus designed to attack cancer cells, in 20 people with intermediate-risk non-muscle invasive bladder cancer. After having visible tumors removed during a scope procedure, patients receive CG0070 directly into the bla…

This study tests whether a combination of two chemotherapy drugs (Gemcitabine and Docetaxel) works as well as the standard BCG treatment for high-grade non-muscle invasive bladder cancer. About 870 patients who have not received BCG before will be randomly assigned to one of the …

This phase 3 study tests whether adding the immunotherapy drug durvalumab to standard BCG treatment helps keep high-risk bladder cancer from coming back. About 1,000 adults with non-muscle-invasive bladder cancer who have not had BCG before will be randomly assigned to get either…

This study tests whether adding a new drug (N-803) to standard BCG therapy works better than BCG alone for people with a high-risk, early-stage bladder cancer. About 369 participants will receive either the combination or BCG alone. The goal is to see if the combo leads to more c…

This study looks at whether a urine test for a genetic marker called SIX6 can predict if low-risk bladder cancer will come back after surgery. Researchers will compare SIX6 levels in 177 patients who had their tumor removed. The goal is to help doctors decide who truly needs foll…

This study is a long-term follow-up for 6 patients who previously received an experimental treatment (N-803 plus BCG) for non-muscle invasive bladder cancer. The goal is to track their cancer status, survival, and any further treatments over time. No new treatment is given; resea…

This study compares two treatments for a type of bladder cancer that keeps coming back: medication placed directly into the bladder versus surgery to remove the bladder. Researchers want to see which option gives patients a better quality of life and fewer side effects. About 570…